Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers

View ORCID ProfileEtienne Brochot, View ORCID ProfileBaptiste Demey, View ORCID ProfileAntoine Touzé, View ORCID ProfileSandrine Belouzard, View ORCID ProfileJean Dubuisson, Jean-Luc Schmit, Gilles Duverlie, View ORCID ProfileCatherine Francois, View ORCID ProfileSandrine Castelain, View ORCID ProfileFrancois Helle
doi: https://doi.org/10.1101/2020.05.12.20098236
Etienne Brochot
aDepartment of Virology, Amiens University Medical Center, Amiens, France.
bAGIR Research Unit, UR UPJV 4294, Jules Verne University of Picardie, Amiens, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Etienne Brochot
  • For correspondence: francois.helle@u-picardie.fr etienne.brochot@u-picardie.fr
Baptiste Demey
aDepartment of Virology, Amiens University Medical Center, Amiens, France.
bAGIR Research Unit, UR UPJV 4294, Jules Verne University of Picardie, Amiens, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Baptiste Demey
Antoine Touzé
cISP1282 INRA University of Tours, Tours, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Antoine Touzé
Sandrine Belouzard
dUniversité Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 8204-CIIL-Center for Infection and Immunity of Lille, F-59000 Lille, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sandrine Belouzard
Jean Dubuisson
dUniversité Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 8204-CIIL-Center for Infection and Immunity of Lille, F-59000 Lille, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jean Dubuisson
Jean-Luc Schmit
aDepartment of Virology, Amiens University Medical Center, Amiens, France.
bAGIR Research Unit, UR UPJV 4294, Jules Verne University of Picardie, Amiens, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gilles Duverlie
aDepartment of Virology, Amiens University Medical Center, Amiens, France.
bAGIR Research Unit, UR UPJV 4294, Jules Verne University of Picardie, Amiens, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catherine Francois
aDepartment of Virology, Amiens University Medical Center, Amiens, France.
bAGIR Research Unit, UR UPJV 4294, Jules Verne University of Picardie, Amiens, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Catherine Francois
Sandrine Castelain
aDepartment of Virology, Amiens University Medical Center, Amiens, France.
bAGIR Research Unit, UR UPJV 4294, Jules Verne University of Picardie, Amiens, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sandrine Castelain
Francois Helle
bAGIR Research Unit, UR UPJV 4294, Jules Verne University of Picardie, Amiens, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Francois Helle
  • For correspondence: francois.helle@u-picardie.fr etienne.brochot@u-picardie.fr
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Summary

Objective The objective of this study was to monitor the anti-SARS-CoV-2 antibody response in infected patients.

Methods In order to assess the time of seroconversion, we used 151 samples from 30 COVID-19 inpatients and monitored the detection kinetics of anti-S1, anti-S2, anti-RBD and anti-N antibodies with in-house ELISAs. We also monitored the presence of neutralizing antibodies in these samples as well as 25 asymptomatic carrier samples using retroviral particles pseudotyped with the spike of the SARS-CoV-2.

Results We observed that specific antibodies were detectable in all inpatients two weeks post-symptom onset. The detection of the SARS-CoV-2 Nucleocapsid and RBD was more sensitive than the detection of the S1 or S2 subunits. Neutralizing antibodies reached a plateau two weeks post-symptom onset and then declined in the majority of inpatients. Furthermore, neutralizing antibodies were undetectable in 56% of asymptomatic carriers.

Conclusions Our results raise questions concerning the role played by neutralizing antibodies in COVID-19 cure and protection against secondary infection. They also suggest that induction of neutralizing antibodies is not the only strategy to adopt for the development of a vaccine. Finally, they imply that anti-SARS-CoV-2 neutralizing antibodies should be titrated to optimize convalescent plasma therapy.

Highlights

  • Specific antibodies are detectable in 100% COVID-19 inpatients two weeks post-symptom onset.

  • The detection of the SARS-CoV-2 Nucleocapsid and Receptor Binding Domain is more sensitive than the detection of the S1 or S2 subunits.

  • Neutralizing antibodies reach a plateau two weeks post-symptom onset and then decline in the majority of inpatients.

  • Neutralizing antibodies are undetectable in the majority of asymptomatic carriers.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by Flash Covid-19 funds from the Amiens University Medical Center and the French Agence Nationale de la Recherche.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the institutional review board of the Amiens University Medical Center (number PI2020_843_0046, 21 April 2020).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Most of the data generated or analysed during this study are included in this published article (and its supplementary information files). Additional supporting data are available from the corresponding authors on request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted June 08, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers
Etienne Brochot, Baptiste Demey, Antoine Touzé, Sandrine Belouzard, Jean Dubuisson, Jean-Luc Schmit, Gilles Duverlie, Catherine Francois, Sandrine Castelain, Francois Helle
medRxiv 2020.05.12.20098236; doi: https://doi.org/10.1101/2020.05.12.20098236
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers
Etienne Brochot, Baptiste Demey, Antoine Touzé, Sandrine Belouzard, Jean Dubuisson, Jean-Luc Schmit, Gilles Duverlie, Catherine Francois, Sandrine Castelain, Francois Helle
medRxiv 2020.05.12.20098236; doi: https://doi.org/10.1101/2020.05.12.20098236

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (496)
  • Anesthesia (106)
  • Cardiovascular Medicine (1110)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (275)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (505)
  • Epidemiology (9796)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2327)
  • Geriatric Medicine (223)
  • Health Economics (463)
  • Health Informatics (1567)
  • Health Policy (737)
  • Health Systems and Quality Improvement (608)
  • Hematology (238)
  • HIV/AIDS (508)
  • Infectious Diseases (except HIV/AIDS) (11669)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (240)
  • Medical Ethics (67)
  • Nephrology (258)
  • Neurology (2154)
  • Nursing (134)
  • Nutrition (340)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (519)
  • Oncology (1185)
  • Ophthalmology (366)
  • Orthopedics (129)
  • Otolaryngology (221)
  • Pain Medicine (148)
  • Palliative Medicine (50)
  • Pathology (314)
  • Pediatrics (699)
  • Pharmacology and Therapeutics (303)
  • Primary Care Research (268)
  • Psychiatry and Clinical Psychology (2195)
  • Public and Global Health (4685)
  • Radiology and Imaging (786)
  • Rehabilitation Medicine and Physical Therapy (458)
  • Respiratory Medicine (625)
  • Rheumatology (276)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (212)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)